The 27 references in paper L. Bolotina V., A. Kornietskaya L., A. Kaprin D., Е. Karpenko Yu., Л. Болотина В., А. Корниецкая Л., А. Каприн Д., Е. Карпенко Ю. (2019) “Первая линия лекарственной терапии плоскоклеточного рака головы и шеи. Оптимальная стратегия // First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy” / spz:neicon:ogsh:y:2018:i:4:p:14-20

1
NCCN guidelines for head and neck cancers, version 1.2018. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/head-and-neck. pdf.
(check this in PDF content)
2
Болотина Л. В., Владимирова Л. Ю., Деньгина Н. В. и др. Практические рекомендации по лекарственному лечению злокачественных опухолей головы и шеи. Злокачественные опухоли 2017;7(3-S2):66–76. [Bolotina L. V., Vladimirova L. Yu., Dengina N. V. et al. Guidelines for medicamental treatment of malignant tumors of the head and neck. Zlokachestvennye opukholi = Malignant tumors 2017;7(3-S2):66–76. (In Russ.)]. DOI: 10.18027/2224-5057-20l7-7-
(check this in PDF content)
3
2-66-76. 3. Состояние онкологической помощи населению России в 2016 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2017. 236 c. [State of cancer care in Russia in 2016. Ed. by A. D. Kaprin, V. V. Starinsky, G. V. Petrova. Moscow, 2017. 236 c. (In Russ.)].
(check this in PDF content)
4
Ghi M. G., Paccaqnella A., Ferrari D. et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial. Ann Oncol 2017;28(9):2206–12. DOI: 10.1093/annonc/mdx299. PMID: 28911070.
(check this in PDF content)
5
Adelstein D. J., Li Y., Adams G. L. et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92–8. DOI: 10.1200/JCO.2003.01.008. PMID: 12506176.
(check this in PDF content)
6
Denis F., Garaud P., Bardet E. et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22(1):69–76. DOI: 10.1200/JCO. 2004.08.021. PMID: 14657228.
(check this in PDF content)
7
Bonner J. A., Harari P. M., Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–78. DOI: 10.1056/NEJMoa053422. PMID: 16467544.
(check this in PDF content)
8
Calais G., Alfonsi M., Bardet E. et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91(24):2081–6. PMID: 10601378.
(check this in PDF content)
9
Curran D., Giralt J., Harari P. M. et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007;25(16):2191–7. DOI: 10.1200/ JCO.2006.08.8005. PMID: 17538164.
(check this in PDF content)
10
Bonner J. A., Harari P. M., Giralt J. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21–8. DOI: 10.1016/S1470-2045(09)70311-0. PMID: 19897418.
(check this in PDF content)
11
Pignon J. P., le Maître A., Maillard E. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4–14. DOI: 10.1016/j.radonc.2009.04.014. PMID: 19446902.
(check this in PDF content)
12
Rosenthal D. I., Harari P. M., Giralt J. et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol 2016; 34(12):1300–8. DOI: 10.1200/JCO. 2015.62.5970. PMID: 26712222.
(check this in PDF content)
13
Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431cell xenografts. Cancer Res 1993;53(19):4637–42. PMID: 8402640.
(check this in PDF content)
14
Argiris A., Harrington K. J., Tahara M. et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck Front Oncol 2017;7:72. DOI: 10.3389/fonc. 2017.00072. PMID: 28536670.
(check this in PDF content)
15
Vermorken J. B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27. DOI: 10.1056/NEJMoa0802656. PMID: 18784101.
(check this in PDF content)
16
Guigay J., Fayette J., Dillies A. F. et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol 2015;26(9):1941–7. DOI: 10.1093/ annonc/mdv268. PMID: 26109631.
(check this in PDF content)
17
Platinum-cetuximab combined with docetaxel or with 5FU in patients with recurrent/metastatic HNSCC (TPExtreme). ClinicalTrials.gov Identifier: Вклад авторов Л. В. Болотина: обзор публикаций по теме статьи, анализ полученных данных, написание текста статьи; А. Л. Корниецкая: получение данных для анализа; А. Д. Каприн: организационная поддержка, анализ полученных данных; Е. Ю. Карпенко: получение данных для анализа. Authors’ contributions L. V. Bolotina: reviewing of publications of the article’s theme, analysis of the obtained data, article writing; А. L. Kornietskaya: obtaining data for analysis; А. D. Kaprin: organizational support, analysis of the obtained data; Е. Yu. Karpenko: obtaining data for analysis. ORCID авторов/ORCID of authors Л. В. Болотина/L. V. Bolotina: https:// orcid.o
(check this in PDF content)
18
Mello R. A., Gerós S., Alves M. P. et al. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution. PLoS One 2014;9(2):e86697. DOI: 10.1371/journal. pone. 0086697. PMID: 24516537.
(check this in PDF content)
19
Burgy M., Barthélémy P., Lefevre F. et al. Cetuximab-carboplatin-5-fluorouracil regimen in elderly patients with recurrent or metastatic head and neck squamous-cell carcinoma: a French retrospective survey. Oncology 2017;93(1):11–7. DOI: 10.1159/000454732. PMID: 28423384.
(check this in PDF content)
20
Nakano K., Marshall S., Taira S. et al. A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab, Ann Oncol 2016;27(Suppl 6). DOI: 10.1093/annonc/mdw376.55.
(check this in PDF content)
21
Linden N., Buter J., Pescott C. P. et al. Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. Eur Arch Otorhinolaryngol 2016;273(2):455–64. DOI: 10.1007/s00405-015-3495-y. PMID: 25876000.
(check this in PDF content)
22
Hecht M., Hahn D., Beutner D. et al. Cetuximab in combination with platinumbased chemotherapy or radiotherapy in ecurrent and/or metastatic SCCHN in a non-selected patient cohort(interim analysis of the phase IV SOCCER trial). Ann Oncol 2016;27(Suppl 6):328–50.
(check this in PDF content)
23
Pinto L., Teixeira M., Casalta J. et al. PO077: Chemotherapy with cetuximab for head and neck squamous cell carcinoma: a retrospective study. Radiother Oncol 2015;114(Suppl 1):40. DOI: 10.1016/S0167-8140(15)34837-4.
(check this in PDF content)
24
Regnier-Gavier O., Coliat P., Carinato H. et al. Recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC): what about second-line chemotherapy combining cetuximab and platinum-doublet after EXTREME protocol? Eur J Cancer 2017;72(Suppl 1): S113. DOI: 10.1016/S0959-8049(17) 30453-7.
(check this in PDF content)
25
Guo Y., Shi M., Yang A. et al. Platinumbased chemotherapy plus cetuximab firstline for Asian patients with recurrent and/ or metastatic squamous cell carcinoma of the head and neck: results of an openlabel, single-arm, multicenter trial. Head Neck 2015;37(8):1081–7. DOI: 10.1002/hed. 23707. PMID: 24710768.
(check this in PDF content)
26
Lawrence M. S., Stojanov P., Polak P. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499(7457):214–8. DOI: 10.1038/nature12213. PMID: 23770567.
(check this in PDF content)
27
Ferris R. L., Blumenschein G. Jr, Fayette J. et al. Nivolumab for recurrent squamouscell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. PMID: 27718784.
(check this in PDF content)